HTRS TE Registry (ThromboEmbolism Registry)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00266994|
Recruitment Status : Completed
First Posted : December 20, 2005
Last Update Posted : February 21, 2013
The TE Registry is a multi-institutional bioinformatics database for the collection of data relevant to TE. Participating HTRS affiliated study centers may enroll patients and enter data in the TE Registry by completing enrollment and data entry forms and transmitting them to the study center. The purpose of this study is to improve our understanding of the epidemiology, pathophysiology, and outcome of patients suffering from thromboembolism (TE) events.
The initial objectives of the registry are:
- Evaluate the epidemiology and clinical characteristics of known prothrombotic risk factors in persons with TE.
- Identify the frequency and nature of complications associated with TE and its treatment.
- Describe the phenotypes and complications seen in persons with multiple molecular risk factors for TE.
- Compare the epidemiology, clinical characteristics, and complications seen in patients with and without known risk factors for TE.
|Condition or disease|
Hereditary defects that predispose to thromboembolism (TE) and its complications afflict 5-8% of the U.S population. Annually, ~60,000 Americans die from TE and half of the survivors suffer long-term morbidity. Despite these staggering statistics, little is known about the clinical characteristics or epidemiology of the inherited risk factors for TE. Less is known regarding the acquired risk factors or the phenotype of TE in persons with multiple risk factors, yet preliminary data suggest that as many as 10% of patients may have multiple risk factors.
Data from several studies, primarily involving adult subjects, shows that in a population of consecutively studied thrombosis patients, that one of the five most common inherited predispositions will occur in ~33.8%. Antithrombin (AT) is the least common (~1.9%) of these, while Factor V Leiden (FVL) is the most common (~18.8%). Most children who suffer from TE have indwelling catheters to assist therapy of underlying medical conditions, or are sick neonates. Thus, the contribution of molecular risk factors in children is largely unknown, with the exception of sparse retrospective data.
The TE Registry may help clearly define the clinical phenotype, epidemiology, and complications seen in patients with TE associated with known molecular risk factors.
|Study Type :||Observational|
|Actual Enrollment :||2760 participants|
|Official Title:||HTRS TE Registry (ThromboEmbolism Registry): Prospective Registry of Demographic and Clinical Data for Patients With Thromboembolic Disease|
|Study Start Date :||December 2005|
|Actual Primary Completion Date :||October 2012|
|Actual Study Completion Date :||October 2012|
- Observation [ Time Frame: 2 years ]Observational cohort study - no primary outcome.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00266994
|United States, Ohio|
|Nationwide Children's Hospital|
|Columbus, Ohio, United States, 43205|
|Principal Investigator:||Bryce A Kerlin, MD||Nationwide Children's Hospital|